Figure 4From: First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus Mean cumulative 24-h urine glucose excretion following single-dose administration of remogliflozin etabonate (20 to 1000 mg) in healthy subjects. Back to article page